Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for ...

VTEX (NYSE: VTEX), the backbone for connected commerce, today announced results for the fourth quarter and fiscal year 2025 ...

Updated data for casdatifan in late-line kidney cancer demonstrated median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% for the 100mg once-daily ...

Q4 Software Operations Bookings Up 14% from Prior Year, and Nearly 83% From the Prior Quarter Year-Over-Year Managed Services Revenue Growth Drives Nearly 5% Growth in Software Revenue Company ...